US · ABSI
Absci Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Vancouver, WA 98683
- Website
- absci.com
Price · as of 2024-12-31
$4.92
Market cap 412.02M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.30 | +414.23% |
| Intrinsic Value(DCF) | $1.46 | -70.33% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $11.00 | +123.66% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $9.02 | $22.05 | $2.59 | $0.00 | $0.00 |
| 2022 | $1.86 | $22.76 | $1.27 | $0.00 | $0.00 |
| 2023 | $5.02 | $24.70 | $0.24 | $0.00 | $0.00 |
| 2024 | $3.12 | $25.30 | $0.34 | $0.00 | $11.00 |
AI valuation
Our deep-learning model estimates Absci Corporation's (ABSI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.30
- Current price
- $4.92
- AI upside
- +414.23%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.46
-70.33% upside
Graham-Dodd
—
— upside
Graham Formula
$11.00
+123.66% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ABSI | Absci Corporation | $4.92 | 412.02M | +414% | -70% | — | +124% | -3.34 | 1.92 | 75.86 | -2.57 | — | 2.56 | -1277.57% | -2401.59% | -2274.06% | -58.04% | -127.20% | -47.86% | 0.06 | -192.72 | 4.67 | 3.92 | 0.33 | -2167.00% | -2071.00% | 1116.00% | -21.17% | -2.53 | -85.05% | 0.00% | 0.00% | 0.00% | -2.22 | -3.32 | 53.29 | 1.58 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| ERAS | Erasca, Inc. | $13.66 | 4.23B | — | — | — | — | -2.21 | 0.84 | — | -0.73 | — | 0.84 | 0.00% | — | — | -43.68% | -151.38% | -36.01% | 0.12 | — | 9.84 | 9.58 | 0.10 | -1687.00% | — | 2814.00% | -36.89% | -3.49 | -111.24% | 0.00% | 0.00% | 0.00% | -0.62 | -0.84 | — | 0.06 |
| GOSS | Gossamer Bio, Inc. | $0.42 | 98.35M | — | +201% | — | — | -4.84 | 9.28 | 2.39 | -4.56 | — | 9.28 | 100.00% | -52.24% | -49.28% | -122.54% | 143.80% | -18.03% | 6.88 | -5.20 | 6.88 | 6.66 | -3.92 | -7881.00% | — | -9782.00% | -1.27% | -0.08 | 8.32% | 0.00% | 0.00% | 8.83% | -3.04 | -52.51 | 1.59 | -4.31 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| PRTA | Prothena Corporation plc | $8.67 | 466.71M | +225% | -47% | — | +4,117% | -2.07 | 1.80 | 52.25 | -1.06 | -2.08 | 1.80 | 0.00% | -1905.82% | -2520.57% | -63.62% | -2799.76% | -55.86% | 0.05 | — | 7.72 | 7.53 | 1.46 | 9956.00% | -9283.00% | 889.00% | -32.36% | -4.01 | -2483.59% | 0.00% | 0.00% | 0.00% | -1.15 | -1.30 | 21.92 | 5.73 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| VSTM | Verastem, Inc. | $5.72 | 346.28M | — | -51% | — | — | -1.91 | -8.65 | 25.00 | -1.62 | — | -8.65 | 100.00% | -1149.56% | -1306.37% | -917.36% | 202.29% | -103.99% | -1.46 | -25.20 | 3.07 | 2.87 | 0.37 | -758.00% | — | 2121.00% | -41.92% | -3.38 | 184.42% | 0.00% | 0.00% | 4.08% | -1.77 | -1.94 | 20.34 | -14.91 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
- CEO
- Sean McClain
- Employees
- 156
- Beta
- 2.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.46 ÷ $4.92) − 1 = -70.33% (DCF, example).